Drug Early Warning from Re-Testing Biological Samples

Post Date

September 16th 2015

Application Due Date

September 22nd 2015

Funding Opportunity Number

ONDCP-DEW-2015

CFDA Number(s)

95.007

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Science and Technology and other Research and Development

Number of Awards

1

Eligibility Categories

Public and State Controlled Institutions of Higher Education

ONDCP encourages applications from public nonprofit institution/organization (includes institutions of higher education and hospitals). Applicants must have expert knowledge and extensive experience in conducting research and analysis. Current awardee is eligible to apply for this funding opportunity.

Funding

• Estimated Total Funding:

  $100000

• Award Range:

  $100000 - $100000

Grant Description

The Office of National Drug Control Policy (ONDCP), Executive Office of the President, is seeking applications from public nonprofit institutions/organizations (includes institutions of higher education and hospitals) to perform research and analysis of data to inform drug policy. This project seeks to further refine a methodology for obtaining drug early warning indicators from expanded testing of urine samples that were previously collected and tested as part of an existing drug test protocol. This method was initially developed using local criminal justice populations _ including persons in pre-trial or lock-up, parolees or probationers, and drug court participants. Similar methodology is promising for use in other venues, such as in trauma units and emergency departments, where biological samples are often collected from patients. Before the specimens are discarded, the project will re-test them for an expanded panel of drugs, including synthetic cannabinoids, to determine what old and new illicit drugs are detected or missed by conventional testing protocols, and how the drug patterns might vary by subpopulation and geography. By passing the expense of collecting the original specimens and re-using those that have already been tested with known results yields a relatively inexpensive and timely picture of emerging drugs in a given subpopulation and locality. ONDCP expects to continue to engage the laboratory testing services of the Armed Forces Medical Examiner System (AFMES) at no charge to further minimize project costs.

Contact Information

• Agency

  Office of National Drug Control Policy

• Office:

  None

• Agency Contact:

  darren neely
  IT specialist
  Phone 2023955530

• Agency Mailing Address:

  email for electronic access problems

• Agency Email Address:

  dneely@ondcp.eop.gov